Pathalys Pharma Inc, a US-based private biopharmaceutical company in the late stages of developing treatments for kidney disease, announced on Tuesday that it has named Bastian Dehmel, MD as its new chief medical officer.

In the new role, Dr Dehmel will be responsible for clinical operations, clinical affairs, clinical sciences, data management/biometrics, and product drug safety. Dehmel is to report to Neal Fowler, Pathalys CEO, and will serve on the senior leadership team.

Dr Dehmel has 20 years of global biotechnology and pharmaceutical industry experience, covering all phases of drug development, clinical operations, biostatistics, and regulatory across several therapeutic areas and international markets. He has served as chief development officer at Oculis SA, chief medical officer of OxThera AB, and in roles of increasing responsibility at Amgen, last serving as global development executive medical director.

Neal Fowler said: "We are thrilled to welcome Bastian as Pathalys' chief medical officer. Throughout his career, Bastian has demonstrated exceptional clinical development leadership, and we are confident that his wealth of experience and deep understanding of calcimimetic clinical research and operations will play a crucial role in advancing our lead asset, upacicalcet, towards a successful clinical and regulatory outcome."